David Moll, MD
Advanced Heart Failure and Transplant Cardiology · Baton Rouge, LANPI 1780846717
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,903 of the $54,657 with a category attached, or 73.0%. 35 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 52.1% of the total.
Across 319 payments — averaging $171.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$28K
- Novartis$15K
- Bayer$5K
- Abbott$2K
- Medtronic$606
- Merck$505
- plus $3K from 29 others
Across 142 payments — averaging $6141.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$825K
- Bayer$47K
What the payments were for
- Speaking & faculty fees$39,90373%
- Travel & lodging$6,10011%
- Food & beverage$8,21915%
- Education$4181%
- Other$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 59 | $28,462 |
| Novartis | 27 | $14,879 |
| Bayer | 12 | $5,447 |
| Abbott | 41 | $1,943 |
| Medtronic(2 entities) | 19 | $606 |
| Merck | 29 | $505 |
| Pfizer | 23 | $429 |
| Alnylam Pharmaceuticals Inc. | 11 | $390 |
| Amgen | 14 | $250 |
| AstraZeneca | 12 | $224 |
| Abiomed | 3 | $200 |
| Johnson & Johnson | 16 | $177 |
| E.r. Squibb & Sons, L.L.C. | 10 | $158 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $135 |
| United Therapeutics Corporation | 4 | $115 |
| Boehringer Ingelheim | 4 | $81 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| Biotronik Inc. | 1 | $65 |
| Atricure, Inc. | 1 | $63 |
| Livanova USA, Inc. | 1 | $63 |
| Kestra Medical Technology Services, Inc. | 2 | $47 |
| Cvrx, Inc. | 1 | $46 |
| Inspire Medical Systems, Inc. | 1 | $45 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Novo Nordisk | 2 | $31 |
| Itamar Medical Inc | 1 | $24 |
| Cleerly, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Chiesi USA, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 60 | $724,885 |
| AdempasRiociguat | 50 | $663,363 |
| VyndamaxTafamidis | 19 | $525,990 |
| EntrestoSacubitril/Valsartan | 205 | $259,869 |
| UptraviSelexipag | 11 | $232,684 |
| EliquisApixaban | 104 | $113,323 |
| JardianceEmpagliflozin | 73 | $69,840 |
| XareltoRivaroxaban | 29 | $31,111 |
| FarxigaDapagliflozin Propanediol | 18 | $21,579 |
| Metoprolol Succinate | 257 | $4,280 |
| Torsemide | 190 | $3,730 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 21 | $2,848 |
| Amiodarone Hcl | 32 | $2,500 |
| Spironolactone | 194 | $2,039 |
| Nitroglycerin | 15 | $1,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $28,462 | $957,56971 claims |
| BayerAdempas | $5,447 | $663,36350 claims |
| PfizerVyndamax, Eliquis | $429 | $639,313123 claims |
| NovartisEntresto | $14,879 | $259,869205 claims |
| Boehringer IngelheimJardiance | $81 | $69,84073 claims |
| Johnson & JohnsonXarelto | $177 | $31,11129 claims |
| AstraZenecaFarxiga | $224 | $21,57918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Baton Rouge
- Phillip SmithBaton Rouge$34K
- Clement EiswirthNew Orleans$277K
- Peter FailHouma$206K
- Shane PrejeanHouma$102K
- Senthil AnandNew Orleans$51K
- Siby AyallooreOpelousas$45K
- Hector VenturaNew Orleans$39K
- Sapna DesaiNew Orleans$30K
- John LawrenceLafayette$17K
- Mohammad El BabaShreveport$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.